@anessabonner's Ozempic video leaves us with questions
Quick answer
The creator describes persistent vomiting and inability to eat for multiple days following a semaglutide injection, consistent with severe GLP-1-associated gastrointestinal adverse events documented in the STEP trial series. Multi-day emesis without oral intake carries dehydration and electrolyte imbalance risk that warrants clinical evaluation, not self-management. The phrase 'another shot' suggests a pattern of recurrent adverse reactions without provider-guided dose adjustment or medical assessment between episodes.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @anessabonner actually say?
She described taking another semaglutide injection, calling herself "stupid" for it, and then experiencing continuous vomiting since Tuesday with no food intake for multiple days. Her closing line was direct: "I don't recommend doing it. Even though you want to be skinny really bad." That's actually a more honest disclosure than most GLP-1 content on this platform. She's describing what sounds like severe gastrointestinal toxicity, not the mild nausea that pharma messaging tends to gloss over. The phrase "another shot" implies she had already reacted badly before and injected again anyway, which is the part worth unpacking clinically.
Does the science back this up?
Yes, and the data is more alarming than most creators acknowledge. Semaglutide's GI side effect profile is well-documented. A 2023 JAMA Internal Medicine study by Sodhi et al. found that GLP-1 receptor agonists were associated with significantly higher risks of pancreatitis, gastroparesis, and bowel obstruction compared to bupropion-naltrexone in patients using these drugs for weight loss. Nausea and vomiting are the most common adverse events across trials, reported in roughly 20-44% of participants in the SUSTAIN and STEP trial series. What she's describing, days of vomiting with zero food intake, sits at the more severe end of that spectrum and borders on what clinicians would flag as dehydration risk requiring evaluation. This is not just "feeling a little queasy."
- Sodhi et al., 2023, JAMA Internal Medicine: GLP-1 agonists linked to gastroparesis and other serious GI events.
- STEP 1 trial (Wilding et al., 2021, NEJM): nausea reported in 44% of semaglutide participants.
- Davies et al., 2021, Diabetes Care: vomiting rates roughly 24% in semaglutide 2.4mg group.
What did they get wrong (or right)?
She got more right than wrong. The experience she described is real, documented, and under-discussed in GLP-1 social media content. Credit where it's due: she didn't romanticize it. However, there are two problems. First, she framed this as a personal choice consequence rather than a medical safety signal. Someone vomiting continuously for multiple days after an injection should contact their prescriber or seek care, not just wait it out. That part was missing. Second, the implicit framing throughout is that the drug's purpose is to "be skinny," which strips away the clinical indication entirely. Semaglutide is FDA-approved for type 2 diabetes (Ozempic) and chronic weight management in qualifying patients (Wegovy). Using it without medical supervision, or continuing after severe adverse reactions without consulting a provider, is where the real risk lives. She called herself "stupid," but the problem isn't stupidity. It's lack of clinical oversight.
What should you actually know?
Persistent vomiting after a GLP-1 injection is not something to push through alone. Multi-day vomiting leads to dehydration and electrolyte imbalance, which can become medically serious. If you are on semaglutide or any GLP-1 and experience vomiting lasting more than 24-48 hours, that is a conversation for your prescriber, not a TikTok comment section. Dose titration exists specifically to reduce these reactions. Most protocols start patients at 0.25mg weekly for a month before increasing, precisely because jumping doses or restarting after a break dramatically increases GI severity. There is also no clinical evidence that pushing through severe side effects speeds up weight outcomes. It just increases your risk of hospitalization. A 2022 analysis in Obesity by Rubino et al. confirmed that slower titration significantly reduced discontinuation due to GI events without sacrificing efficacy. Suffering through it is not the strategy.
- Contact your prescriber if vomiting lasts beyond 24-48 hours after injection.
- Do not skip the titration phase. Lower starting doses exist for a reason.
- Dehydration from prolonged vomiting can require IV fluids and medical intervention.
- Restarting semaglutide after a break may require stepping back down in dose.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @anessabonner's Ozempic video leaves us with questions, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Claim verdict
The useful answer behind this video
Claim being checked
The creator describes persistent vomiting and inability to eat for multiple days following a semaglutide injection, consistent with severe GLP-1-associated gastrointestinal adverse events documented in the STEP trial series.
FormBlends verdict
The creator describes persistent vomiting and inability to eat for multiple days following a semaglutide injection, consistent with severe GLP-1-associated gastrointestinal adverse events documented in the STEP trial series. Multi-day emesis without oral intake carries dehydration and electrolyte imbalance risk that warrants clinical evaluation, not self-management. The phrase 'another shot' suggests a pattern of recurrent adverse reactions without provider-guided dose adjustment or medical assessment between episodes.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator describes persistent vomiting and inability to eat for multiple days following a semaglutide injection, consistent with severe GLP-1-associated gastrointestinal adverse events documented in the STEP trial series. Multi-day emesis without oral intake carries dehydration and electrolyte imbalance risk that warrants clinical evaluation, not self-management. The phrase 'another shot' suggests a pattern of recurrent adverse reactions without provider-guided dose adjustment or medical assessment between episodes.
- Vomiting is reported in up to 44% of semaglutide users in clinical trials (Wilding et al., 2021, NEJM), making it the most common reason for dose reduction or discontinuation.
- Multi-day vomiting without food intake is a medical situation. Dehydration and electrolyte imbalance can develop quickly and may require IV fluids or emergency evaluation.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- Vomiting is reported in up to 44% of semaglutide users in clinical trials (Wilding et al., 2021, NEJM), making it the most common reason for dose reduction or discontinuation.
- Multi-day vomiting without food intake is a medical situation. Dehydration and electrolyte imbalance can develop quickly and may require IV fluids or emergency evaluation.
- Slower titration dramatically reduces severe GI side effects. Standard protocols begin at 0.25mg weekly for four weeks before any increase. Rubino et al. (2022, Obesity) confirmed this reduces discontinuation without sacrificing weight outcomes.
- Restarting semaglutide after stopping, even briefly, typically requires stepping the dose back down. Jumping back to a prior dose after a gap significantly increases GI reaction severity.
- Sodhi et al. (2023, JAMA Internal Medicine) found GLP-1 receptor agonists associated with higher rates of gastroparesis and bowel obstruction compared to other weight-loss medications, particularly outside supervised clinical settings.
- Semaglutide sold as Ozempic is FDA-approved for type 2 diabetes management. Wegovy carries the FDA approval for chronic weight management. Using either without a licensed prescriber and proper monitoring removes the safety infrastructure the drug's approval was built around.
- If you are experiencing severe or prolonged GI side effects on any GLP-1 medication, contact your prescriber before your next injection, not after.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Anessa behind the block · TikTok creator
40.4K views on this video
Ozempic #arkansas #f #sick
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Anessa behind the block, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.